builderall

Conference Description

This annual educational conference is developed in collaboration with the academic faculty and scientists of the California Cancer Consortium to provide an in-depth, evidence-based review of emerging advances in oncologic drug development, cancer biology, biomarkers, diagnosis, and systemic therapies for solid and hematologic malignancies.

The conference is designed to address identified practice gaps and underlying educational needs of the interprofessional oncology care team, based on prior participant evaluations and feedback from practicing clinicians and research professionals involved in cancer care and clinical trials. The agenda emphasizes clinical application of new data and supports the healthcare team in translating advances into individualized, high-quality cancer care.

This meeting brings together physicians, advanced practice providers, nurses, pharmacists, and clinical research professionals to engage in active learning through expert-led lectures, case-based discussions, and interactive roundtables. Educational strategies are intentionally structured to promote learning with, from, and about each profession’s roles and responsibilities, strengthening interprofessional communication and teamwork across the cancer consortium.

It is expected that participation in this educational activity will enhance clinical competence, improve interprofessional collaborative practice, and support measurable improvements in care processes and patient outcomes for individuals living with cancer.

Learner Objectives

Upon completion of this activity, participants will be better able to:

  • Identify key signaling, biomarker, and immunotherapeutic pathways involved in tumor development, progression, and metastasis across major malignancies.

  • Apply advances in molecular phenotyping and biomarker-driven diagnostics to optimize systemic therapy selection and management strategies.

  • Assess evidence from recent clinical trials to evaluate efficacy, safety, and appropriate patient selection for emerging therapeutic strategies (e.g., targeted agents, antibody-drug conjugates, immunotherapies).

  • Collaborate effectively as an interprofessional oncology care team to identify patient-specific opportunities for therapeutic intervention and supportive care planning.

  • Integrate new and evolving clinical trial designs into shared decision-making and trial referral processes within clinical and research workflows to improve patient access to innovative therapies.

Target Audience

This activity is designed for members of the oncology healthcare team involved in cancer diagnosis, treatment planning, systemic therapy delivery, supportive care, and clinical research, including:

Medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellows and residents, advanced practice providers, registered nurses, physician assistants, pharmacists, clinical research coordinators, biostatisticians, and other professionals engaged in oncologic drug development and cancer clinical care.

Expected attendance: 75–100 participants.